H MOHANKUMAR: Open Payments
NPI 1114080314 · ORANGE, CA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,639 in 19 payments from 7 companies in 2025. Trend: 2023 $2,482 · 2024 $1,692 · 2025 $1,639
Food & beverage: $1,639
| Company | Payments | Amount |
|---|---|---|
| Janssen Pharmaceuticals, Inc | 4 | $396 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 4 | $297 |
| Alkermes, Inc. | 3 | $279 |
| Otsuka America Pharmaceutical, Inc. | 2 | $235 |
| E.R. Squibb & Sons, L.L.C. | 3 | $182 |
| Teva Pharmaceuticals USA, Inc. | 2 | $125 |
| Vanda Pharmaceuticals Inc. | 1 | $125 |
Products named: CAPLYTA, INVEGA SUSTENNA, LYBALVI, COBENFY, UZEDY, REXULTI, SPRAVATO, FANAPT.
Industry payments across CA — which companies pay providers there.
